Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011.

Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the same period in 2010. For the 12 months ended December 31, 2011, total operating expenses were $93.1 million, as compared to $35.8 million for the same period in 2010.  Increased operating expenses for the fourth quarter of 2011 and for the full calendar year compared to the same periods in 2010 are primarily due to increased research and development expenses associated with our Phase 2b PEARL-SC clinical study in patients with Systemic Lupus Erythematosus, or lupus, and our VISTA-16 clinical study in patients with Acute Coronary Syndrome, or ACS.

Anthera ended the fourth quarter of 2011 with approximately $67.4 million in cash and cash equivalents and short-term investments.  This is compared to $93.3 million in cash and cash equivalents and short-term investments for the third quarter ended September 30, 2011.

In conjunction with the release of the fourth quarter 2011 financial report, Anthera will host a conference call at 1 p.m. Eastern Time today, February 21, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 47038854. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 47038854.  The audio replay will be available until February 28, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • In December 2011, the VISTA-16 Data Safety Monitoring Board (
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/24/2015)... -- Boston Scientific Corporation (NYSE: BSX ) is scheduled ... Healthcare Conference on May 6 in Boston ... and chief financial officer, and Susie Lisa , vice ... answer session regarding the company with the host analyst at ... the presentation and question and answer session will be available ...
    (Date:4/24/2015)... 2015  Novartis Pharmaceuticals Corporation (NPC) has been named the ... row on the annual DiversityInc Top 50 Companies for Diversity ... Companies for Diversity on April 23 at an awards ceremony ... ranked second on the DiversityInc Top 10 Companies for Recruitment ... Resource Groups list. David Epstein , ...
    (Date:4/24/2015)... 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or ... quality medical marijuana products and a licensed producer ("LP") ... Regulations ( Canada ) ("MMPR"), is pleased ... shareholders, has closed the transaction announced on March 11, ... (the "Escrow Transfer") a total of 20,156,790 common shares ...
    Breaking Medicine Technology:Boston Scientific To Participate In The Deutsche Bank 40th Annual Healthcare Conference 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3
    ... 2011 On Wednesday, April 27 at 11 a.m., ... Langevin, Governor Lincoln Chafee, Lieutenant Governor Elizabeth H. Roberts, ... at its headquarters at 211 Circuit Drive in North ... Peter F. Kilmartin will tour Dominion,s laboratory at 1 ...
    ... JACKSON, Wis., April 25, 2011 Wisconsin Pharmacal Company, ... market recall of Triad Povidone Iodine Prep Pads, manufactured ... names including Triad. The Triad Povidone Iodine Prep Pads ... distributed by Wisconsin Pharmacal Company. In the interest of ...
    Cached Medicine Technology:Dominion Diagnostics Celebrates National Medical Laboratory Professionals Week with Rhode Island Elected Officials 2Important Information for Atwater Carey First Aid Kit Consumers Regarding Triad Group's Povidone Iodine Prep Pads 2
    (Date:4/24/2015)... York, NY (PRWEB) April 24, 2015 ... sober living residence in Westchester County. Just 35 miles ... help transition individuals back into everyday life while recovering ... Thursday, May 7, 2015, will allow therapists, doctors and ... areas and learn more about the opportunities offered by ...
    (Date:4/24/2015)... Foothill Ranch, California (PRWEB) April 24, 2015 ... that has a wide range of capabilities and services ... etc. , Ryadon's Quantity Discount Program will be ... ) as follows: , Order 4-19: Receive 10% discount ... Can Benefit by Using the Drawer Slides Products, ...
    (Date:4/24/2015)... York (PRWEB) April 24, 2015 ... move forward in the federal multidistrict litigation underway ... According to court documents, the parties involved in ... April 16th detailing, among other things, preparation for ... that counsel for both plaintiffs and defendants have ...
    (Date:4/24/2015)... The first step to transforming one’s life ... meditation and yoga teacher Stine Koppernæs, meditation and changing ... that allow her to experience more peace and freedom ... teacher since 2006, and through the years she has ... , “I love sharing this way of finding true, ...
    (Date:4/24/2015)... Anchor Health Administrators (Anchor), specialists in Long-Term Care ... exclusive agreement with LTC Solutions for All LLC (SFA) ... , Anchor has more than 18 years of experience ... and is currently the designated advocate for the American ... member benefit. , “I am very pleased to be ...
    Breaking Medicine News(10 mins):Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
    ... Millions of Americans have an undiagnosed artery disorder that can ... study reveals. The disorder is fibromuscular dysplasia, an accumulation ... narrow. The condition can occur in any artery but occurs ... to 4 percent of Americans. If untreated, fibromuscular dysplasia ...
    ... request that the journals Science and ... modified H5N1 virus because of biosecurity concerns does not ... They caution, however, that a fair, transparent process ... on disseminating scientific information., Writing in Science , ...
    ... are not as fit as earlier generations, and even the ... of inactivity could have a major long-term health impact. ... on a survey of Norwegian schoolchildren,s performance in the 3 ... Leif Inge Tjelta and Sindre Dyrstad at the University of ...
    ... , ROCHESTER, Minn. -- Results of two studies suggest ... developed in a collaboration between Mayo Clinic and Exact ... significantly more sensitive than other noninvasive tests at detecting ... important implications for clinicians and tens of thousands of ...
    ... of new federal legislation, electronic health records (EHRs) are ... nurses the frontline providers of care. In the ... University of Pennsylvania School of Nursing determined that nurses ... care and better health outcomes for patients than nurses ...
    ... investigational drug called regorafenib slowed the progression of tumors and ... , an international phase III clinical trial found. The findings ... the American Society of Clinical Oncology in San Francisco ... , principal investigator of the trial in the United States. ...
    Cached Medicine News:Health News:Narrowed Artery Condition Often Goes Undiagnosed: Study 2Health News:Balancing scientific freedom and national security 2Health News:Balancing scientific freedom and national security 3Health News:Sitting it out 2Health News:Sitting it out 3Health News:New test offers greater accuracy in early detection of colorectal cancer 2Health News:New test offers greater accuracy in early detection of colorectal cancer 3Health News:Better together - The RN and the EHR 2Health News:Drug improves survival of colorectal cancer patients, trial results show 2
    ... Super Pulse sealed CO2 surgical lasers offer ... the experience and support services of a ... laser experience. All settings are available at ... MD Super Pulse surgical lasers are compatible ...
    ... and targeting make treatment quick and effective ... cone angle, adjustable offset and variable pulse ... on the most modern IOLs without damage ... optics ensure low energy plasma formation with ...
    ... Pentacam images the anterior segment of the ... This rotating process supplies pictures in three ... measured very precisely because of this rotational ... than two seconds and minute eye movements ...
    ... SP-2000P Non -Contact Specular Microscope is ... and versatility in non-contact specular microscopy. ... Topcon's Imagenet system. Dual measurement system: ... 3D auto alignment and auto capture ...
    Medicine Products: